Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$81.87K$81.87Kderivedno prior Q4 2023 on file Net Income-$230.91K-$230.91KderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$86,588— Operating Incomederived-$178,867— Operating Cash Flowderived-$178,210N/M Margins · derivedGross margin105.8%
Operating margin-218.5%
Net margin-282.0%
ended Dec 31, 2024 · filed Feb 17, 2026 · 413 d after period end